4.6 Article

Development of the first geldanamycin-based HSP90 degraders

期刊

FRONTIERS IN CHEMISTRY
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fchem.2023.1219883

关键词

cancer; cereblon; heat shock protein; Hsp90; PROTAC

向作者/读者索取更多资源

Despite limitations with HSP90 inhibitors as anticancer drugs, a new approach using PROTACs to degrade the protein shows promise. This study focuses on designing and evaluating geldanamycin-based HSP90 degraders based on the PROTAC technology. The best degrader, 3a, effectively reduced HSP90 alpha and HSP90 beta levels in cells using the ubiquitin-proteasome pathway.
Despite the early clinical promise, adverse events such as acquired resistance and dose-limiting toxicities have barred the widespread use of HSP90 inhibitors as anticancer drugs. A new approach involving proteolysis-targeting chimeras (PROTACs) to degrade the protein instead of inhibiting it may overcome these problems. In this work, we describe the design, synthesis, and evaluation of cereblon-recruiting geldanamycin-based HSP90 degraders based on the PROTAC technology. Our best degrader, 3a, effectively decreased HSP90 alpha and HSP90 beta levels in cells utilizing the ubiquitin-proteasome pathway.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据